Cooperation framework agreement signed between Yaoming biology and Anke biological needle in the development of dual anti-tumor drugs

Dec 25, 2018 / Meitong news agency / -- the world's leading open biopharmaceutical technology platform company, Yaoming bio, announced today that it has officially signed a cooperation framework agreement with Anke bio, and the two sides have reached cooperation on the development of an anti-tumor bispecific antibody According to the content of the agreement, Anke biology will use the dual anti-virus platform wuxibody with independent intellectual property rights of YaoMing biology Gamma To develop and innovate a new generation of tumor immunotherapy with bispecific antibody layout Through strong alliance, the two sides make full use of their respective advantages and resources to cooperate in R & D and other aspects, so as to achieve win-win cooperation in the field of biomedical R & D At present, there are nearly ten mAb research projects in the field of research, development, production and sales of biomedicine, which is in the leading position in the research and development of antibody drugs in China Through this cooperation, Yaoming biology will enable Anke biology to accelerate the development process of innovative antibody drugs such as anti-tumor double antibody project and benefit the vast number of patients About wuxibody Gamma WuXiBody Gamma It is a bispecific antibody technology platform with independent intellectual property rights, and is expected to become one of the best bispecific antibody platforms in the industry This platform has broken through the technical bottleneck of most bispecific antibody platforms, effectively overcome the challenges of low expression, high polymer and low purification yield in the development process of bispecific antibodies, and has the advantages of saving 6-18 months of R & D time for each project and significantly reducing the production cost of bispecific antibodies At present, the expression of bispecific antibody is up to 16g / L, and the purity and yield of purified protein A are over 95% Meanwhile, wuxibody Gamma The platform also has unique flexibility to build a variety of valence numbers (such as bivalent, trivalent or tetravalent bispecific antibodies) and structures to meet the biological characteristics of different projects About Anke biosafety, it has been committed to the research, development, production and sales of biomedicine The company attaches great importance to R & D innovation, deeply implements the innovation driven strategy, and has a solid foundation for technology development and industrialization A series of industrial chain layout of precision medicine has been formed, including gene detection, targeted anti-tumor drug development, cell immunotherapy technology, etc At present, there are nearly ten monoclonal antibody research projects in Anke biology, which is in the leading position in the research and development of antibody drugs in China The company will adhere to the leading role of Biopharmaceutics, aim at the cutting-edge technology of Biopharmaceutics development, follow the business policy of "one main and two wings", continuously improve the influence and position of the company in the pharmaceutical industry, and realize the sustainable development of the company As a Hong Kong listed company, Yaoming bio pharmaceutical is the world's leading open and integrated platform for biopharmaceutical capability and technology enabling The company provides a full range of end-to-end R & D services for global biopharmaceutical companies and biotechnology companies, helps anyone and any company to discover, develop and produce biopharmaceuticals, realizes the whole process from concept to commercial production, accelerates the global R & D process of biopharmaceuticals, reduces the cost of research and development, and benefits patients As of June 30, 2018, 187 comprehensive projects have been developed on the platform, including 98 in the preclinical research stage, 78 in the early clinical stage (phase I, phase II), 10 in the late clinical stage (phase III) and 1 in the commercial production stage It is estimated that by 2021, the total capacity of the company's planned biopharmaceutical production bases in China, Ireland, Singapore and the United States will be about 220000 liters, which will effectively ensure that the company will provide customers with biopharmaceuticals that meet global quality standards through a sound and strong global supply chain network.